Literature DB >> 3137170

Hamster challenge potency assay for evaluation of Mycoplasma pneumoniae vaccines.

M F Barile1, D K Chandler, H Yoshida, M W Grabowski, S Razin.   

Abstract

A hamster immunization challenge assay described in the accompanying paper (M. F. Barile, D. K. F. Chandler, H. Yoshida, M. W. Grabowski, R. Harasawa, and S. Razin, Infect. Immun. 56:2443-2449, 1988) was used to examine protection against Mycoplasma pneumoniae disease by passive immunization and to evaluate the protective potency of a Formalin-inactivated whole-cell and a cell extract M. pneumoniae vaccine. Passive immunization with a globulin fraction of hyperimmune mule antiserum to M. pneumoniae provided hamsters some protection against the challenge. When hamsters were actively immunized, a single dose of Formalin-inactivated vaccine provided only minimal protection, whereas multiple doses of this vaccine, particularly when combined with adjuvant, provided good protection. A single dose of the cell extract vaccine did not protect animals, but two doses caused a marked reduction of disease when a priming dose was given intraperitoneally, followed by a booster dose intratracheally. The correlation between the level of metabolism inhibition antibodies to M. pneumoniae in the sera of vaccinated hamsters and the degree of protection as measured by reduction of lung pathological scores and colonization was poor, indicating that seroconversion rates for metabolism inhibition antibodies are not by themselves adequate to measure the potency of M. pneumoniae vaccines.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137170      PMCID: PMC259587          DOI: 10.1128/iai.56.9.2450-2457.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Protective Effect of Vaccines in Experimental Mycoplasma pneumoniae Disease.

Authors:  G W Fernald; W A Clyde
Journal:  Infect Immun       Date:  1970-06       Impact factor: 3.441

2.  Antibody to Mycoplasma pneumoniae in nasal secretions and sputa of experimentally infected human volunteers.

Authors:  H Brunner; H B Greenberg; W D James; R L Horswood; R B Couch; R M Chanock
Journal:  Infect Immun       Date:  1973-10       Impact factor: 3.441

3.  Immunogenicity and protective effect of hemolysis mutants of Mycoplasma pneumoniae.

Authors:  M Yayoshi; M Araake; E Hayatsu; T Takezawa; M Yoshioka
Journal:  Microbiol Immunol       Date:  1985       Impact factor: 1.955

4.  Priming and suppression of the intestinal immune response to cholera toxoid/toxin by parenteral toxoid in rats.

Authors:  N F Pierce; F T Koster
Journal:  J Immunol       Date:  1980-01       Impact factor: 5.422

5.  Ciliostatic, hemagglutinating, and proteolytic activities in a cell extract of Mycoplasma pneumoniae.

Authors:  D K Chandler; M F Barile
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

6.  Hamster challenge potency assay for evaluation of Mycoplasma pneumoniae vaccines.

Authors:  M F Barile; D K Chandler; H Yoshida; M W Grabowski; R Harasawa; O A Ahmed
Journal:  Isr J Med Sci       Date:  1981-07

7.  Mycoplasma pneumoniae adhesin localized to tip structure by monoclonal antibody.

Authors:  J Feldner; U Göbel; W Bredt
Journal:  Nature       Date:  1982-08-19       Impact factor: 49.962

8.  Immunization, isolation of immunoglobulins, estimation of antibody titre.

Authors:  N Harboe; A Ingild
Journal:  Scand J Immunol Suppl       Date:  1973

9.  Acquired immunity to Mycoplasma pneumoniae. Pneumonia in hamsters.

Authors:  E Hayatsu
Journal:  Microbiol Immunol       Date:  1978       Impact factor: 1.955

10.  Protective efficacy of Mycoplasma pneumoniae polysaccharides.

Authors:  H Brunner
Journal:  Isr J Med Sci       Date:  1981-07
View more
  6 in total

1.  Characterization of the cellular response of spleen cells in BALB/c mice inoculated with Mycoplasma pneumoniae or the P1 protein.

Authors:  K Pietsch; E Jacobs
Journal:  Med Microbiol Immunol       Date:  1993-05       Impact factor: 3.402

Review 2.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

3.  Parameters of Mycoplasma pneumoniae infection in Syrian hamsters.

Authors:  M F Barile; D K Chandler; H Yoshida; M W Grabowski; R Harasawa; S Razin
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

4.  The immunodominant 90-kilodalton protein is localized on the terminal tip structure of Mycoplasma pneumoniae.

Authors:  G Franzoso; P C Hu; G A Meloni; M F Barile
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

5.  Immunoblot analyses of chimpanzee sera after infection and after immunization and challenge with Mycoplasma pneumoniae.

Authors:  G Franzoso; P C Hu; G A Meloni; M F Barile
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

6.  Identification of a mechanism for lung inflammation caused by Mycoplasma pneumoniae using a novel mouse model.

Authors:  Takeshi Saraya; Koh Nakata; Kazuhide Nakagaki; Natsuki Motoi; Kuniko Iihara; Yasunori Fujioka; Teruaki Oka; Daisuke Kurai; Hiroo Wada; Haruyuki Ishii; Haruhiko Taguchi; Shigeru Kamiya; Hajime Goto
Journal:  Results Immunol       Date:  2011-11-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.